CELLAÏON
Live / Registered — Registered (as of 05 Mar 2024)
What this means for you
Registered since 05 Mar 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79346877
- Registration number
- 7318105
- Mark type
- Stylized text
- Filed
- 16 Jun 2022
- Published for opposition
- 19 Dec 2023
- Registered
- 05 Mar 2024
- Attorney of record
- Clifford D Hyra
Goods and services
- Class 005 — Pharmaceuticals: Cells originating from human tissue, for medical, clinical or veterinary use, namely, liver derived cells and stem cells or liver progenitor cells; pharmaceutical preparations in the field of liver derived cells and stem cells or liver progenitor cells for the treatment of diseases that require cell therapy medicinal products, namely, liver diseases, chronic biliary diseases, cholestatic diseases, age-related diseases, bone and cartilage disorders, pancreatic diseases, kidney diseases, pulmonary diseases, cardiovascular diseases, eye diseases, ocular diseases, organ injury, organ failure, blood coagulation disorders, Clarkson disease, diabetes, skin diseases, cancer, metabolic diseases, inflammatory diseases, inflammation, neurodegenerative diseases, fibrotic diseases, proliferative diseases, infectious diseases, autoimmune diseases, diseases with unwanted immune response, sepsis, sepsis induced diseases, cellular senescence; surgical implants comprised of living tissue grown from stem cells or progenitor cells in the field of liver derived cells and stem cells or liver progenitor cells; transplants being living tissue in the form of liver derived cells and stem cells or liver progenitor cells; live organs and tissues for surgical purpose in the field of liver derived cells and stem cells or liver progenitor cells; surgical implants comprising living tissue grown from stem cells or progenitor cells in the field of liver derived cells and stem cells or liver progenitor cells; cell-based pharmaceutical preparations in the field of liver derived cells and stem cells or liver progenitor cells for the treatment of liver diseases, chronic biliary diseases, cholestatic diseases, age-related diseases, bone and cartilage disorders, pancreatic diseases, kidney diseases, pulmonary diseases, cardiovascular diseases, eye diseases, ocular diseases, organ injury, organ failure, blood coagulation disorders, Clarkson disease, diabetes, skin diseases, cancer, metabolic diseases, inflammatory diseases, inflammation, neurodegenerative diseases, fibrotic diseases, proliferative diseases, infectious diseases, autoimmune diseases, diseases with unwanted immune response, sepsis, sepsis induced diseases, cellular senescence
- Class 042 — Scientific and technological services: Biomedical research and development services in relation to the testing of biological samples to determine the presence and activity of stem cells, progenitor cells and liver cells, in particular, liver stem cells and liver progenitor cells
Owner
Prosecution history
- 06 Jun 2024 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 06 Jun 2024 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 11 Mar 2024 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 05 Mar 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 05 Mar 2024 — REGISTERED-PRINCIPAL REGISTER
- 21 Feb 2024 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 21 Feb 2024 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 21 Dec 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 21 Dec 2023 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
- 21 Dec 2023 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 21 Dec 2023 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 19 Dec 2023 — NOTIFICATION PROCESSED BY IB
- 19 Dec 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 19 Dec 2023 — PUBLISHED FOR OPPOSITION
- 29 Nov 2023 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB